Chime Biologics Announces Strategic Collaboration with TNAX Biopharma, Marking Its First Partnership in Japan

Article Date
December 9, 2025

This article is featured on another website.

Go to article

Related posts

Browse all articles
July 14, 2026

Chime Biologics Congratulates Polpharma Biologics on Global Licensing Agreement with Teva for Ocrelizumab Biosimilar Candidate

July 14, 2026

Chime Biologics Congratulates Polpharma Biologics on Global Licensing Agreement with Teva for Ocrelizumab Biosimilar Candidate

August 13, 2026

The Oligodendrocyte Advantage

August 13, 2026

The Oligodendrocyte Advantage